CA2444814A1 - Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures - Google Patents

Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures Download PDF

Info

Publication number
CA2444814A1
CA2444814A1 CA002444814A CA2444814A CA2444814A1 CA 2444814 A1 CA2444814 A1 CA 2444814A1 CA 002444814 A CA002444814 A CA 002444814A CA 2444814 A CA2444814 A CA 2444814A CA 2444814 A1 CA2444814 A1 CA 2444814A1
Authority
CA
Canada
Prior art keywords
coating layer
poly
methacrylic acid
methyl methacrylate
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002444814A
Other languages
English (en)
Other versions
CA2444814C (fr
Inventor
Gregory Paul Dittmar
Joseph Michael Amante
Tony Ryan Cronk
Daniel Gary Newby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29783760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2444814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority claimed from CA002359812A external-priority patent/CA2359812C/fr
Publication of CA2444814A1 publication Critical patent/CA2444814A1/fr
Application granted granted Critical
Publication of CA2444814C publication Critical patent/CA2444814C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
CA002444814A 2001-10-24 2001-10-24 Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures Expired - Lifetime CA2444814C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002359812A CA2359812C (fr) 2000-11-20 2001-10-24 Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002359812A Division CA2359812C (fr) 2000-11-20 2001-10-24 Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures

Publications (2)

Publication Number Publication Date
CA2444814A1 true CA2444814A1 (fr) 2002-05-20
CA2444814C CA2444814C (fr) 2009-06-09

Family

ID=29783760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444814A Expired - Lifetime CA2444814C (fr) 2001-10-24 2001-10-24 Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures

Country Status (1)

Country Link
CA (1) CA2444814C (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597293B2 (en) 2007-05-07 2017-03-21 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP3162362A1 (fr) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Comprimé optimisé a une haute dose contenant de la mesalazine

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597293B2 (en) 2007-05-07 2017-03-21 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP2152250B1 (fr) * 2007-05-07 2019-09-04 Evonik Röhm GmbH Formes posologiques solides comprenant un revêtement gastrorésistant et présentant une libération accélérée du médicament
US10537530B2 (en) 2007-05-07 2020-01-21 Evonik Operations Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP3162362A1 (fr) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Comprimé optimisé a une haute dose contenant de la mesalazine
WO2017072050A1 (fr) * 2015-10-30 2017-05-04 Dr. Falk Pharma Gmbh Comprimé optimisé hautement dosé contenant de la mésalazine
US11135159B2 (en) 2015-10-30 2021-10-05 Dr. Falk Pharma Gmbh Optimized high-dose mesalazine-containing tablet

Also Published As

Publication number Publication date
CA2444814C (fr) 2009-06-09

Similar Documents

Publication Publication Date Title
CA2359812A1 (fr) Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
IL161628A0 (en) Pharmaceutical dosage form with multiple coatings
US6103266A (en) Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
EP1275381A4 (fr) Compositions solides enrobees a liberation decalee dans le temps
US5686094A (en) Controlled release formulations for the treatment of xerostomia
KR100283709B1 (ko) 안정한 서방성 경구 투여 조성물
US5102666A (en) Calcium polycarbophil controlled release composition and method
WO2004108162A3 (fr) Composition pharmaceutique et methode de traitement
CA2277365A1 (fr) Traitement de la sclerose en plaques par l'ingestion ou l'inhalation de copolymere-1
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
JP2005515966A5 (fr)
CA2238271A1 (fr) Compositions pharmaceutiques comprenant du flurbiprofene
JP2006514058A (ja) 薬物の経口投与用の急速溶解フィルム
ES2611995T3 (es) Métodos y composiciones para el suministro de un agente terapéutico
WO2004002445A3 (fr) Nouvelles formes posologiques flottantes
WO2002017855A3 (fr) Preparation de compositions pharmaceutiques a utiliser avec des formulations gelatineuses molles
JPH059412B2 (fr)
CA2143413A1 (fr) Pellicule liberant un medicament localement pour le traitement periodontique
EP0497956B1 (fr) Formulations de liberation controlee
CA2415957A1 (fr) Formulation de poudre seche contenant du racecadotril
CN108338976A (zh) 一种硝苯地平双层渗透泵片及其制备方法
CA2444814A1 (fr) Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
US20200323834A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof
CA2472449A1 (fr) Compositions pharmaceutiques presentant une meilleure absorption orale
EP0664709A1 (fr) Composition pharmaceutique contenant un agent antimicrobien et un antibiotique

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20211025